Artera announced that the ArteraAI Prostate Test (Post-RP) has been included in the updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer (Version 1.2027), as a risk stratification tool for patients experiencing biochemical recurrence (BCR) following radical prostatectomy.
Artera’s tests are the only AI-based risk stratification tools included in the NCCN Guidelines for Prostate Cancer, and one of only two tests included across three patient groups: intermediate-risk, high-risk, and biochemical recurrence. The update builds on the 2024 inclusion of the ArteraAI Prostate Test in the guidelines for localized prostate cancer.
The ArteraAI Prostate Test (Post-RP) analyzes digitized surgical pathology images and clinical data, without requiring additional tissue, to stratify patients by risk of disease progression and help inform treatment decisions for patients experiencing BCR following radical prostatectomy.
